Abstract:Despite advances in the treatment of acute myeloid leukemia (AML), relapse is still widely observed and represents the major cause of death among patients with AML. Treatment options in the relapse setting are limited, still relying predominantly on allogeneic hematopoietic stem cell transplantation (allo-HSCT) and cytotoxic chemotherapy, with poor outcomes. Novel targeted and venetoclax-based combinations are being investigated and have shown encouraging results. Immune checkpoint inhibitors in combination with low-intensity chemotherapy demonstrated encouraging response rates and survival among patients with relapsed and/or refractory (R/R) AML, especially in the pre- and post-allo-HSCT setting. Blocking the CD47/SIRPα pathway is another strategy that showed robust anti-leukemic activity, with a response rate of around 70% and an encouraging median overall survival in patients with newly diagnosed, higher-risk myelodysplastic syndrome and patients with AML with a TP53 mutation. One approach that was proven to be very effective in the relapsed setting of lymphoid malignancies is chimeric antigen receptor (CAR) T cells. It relies on the infusion of genetically engineered T cells capable of recognizing specific epitopes on the surface of leukemia cells. In AML, different CAR constructs with different target antigens have been evaluated and demonstrated safety and feasibility in the R/R setting. However, the difficulty of potently targeting leukemic blasts in AML while sparing normal cells represents a major limitation to their use, and strategies are being tested to overcome this obstacle. A different approach is based on endogenously redirecting the patient’s system cells to target and destroy leukemic cells via bispecific T-cell engagers (BiTEs) or dual antigen receptor targeting (DARTs). Early results have demonstrated the safety and feasibility of these agents, and research is ongoing to develop BiTEs with longer half-life, allowing for less frequent administration schedules and developing them in earlier and lower disease burden settings.

Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia

Modified Cladribine, Cytarabine, and G-CSF As a Salvage Regimen in Patients with Relapsed/refractory Acute Myeloid Leukemia: a Bridge to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation

How I treat refractory and relapsed acute myeloid leukemia

Progress on the Diagnosis and Treatment of Refractory Leukemia

Targeting Acute Myeloid Leukemia Stem Cells: Current Therapies in Development and Potential Strategies with New Dimensions

A review of treatment options employed in relapsed/refractory AML

Research Progress of Novel Drugs for Treatment of Acute Myeloid Leukemia

Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024

The Landscape of Novel Strategies for Acute Myeloid Leukemia Treatment: Therapeutic Trends, Challenges, and Future Directions

Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective

An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!

Progress in the Treatment of Acute Promyelocytic Leukemia: Optimization and Obstruction

Precision Therapy for Acute Myeloid Leukemia

CAR-NK Cells for Acute Myeloid Leukemia Immunotherapy: Past, Present and Future.

Single-cell Analysis Reveals the Chemotherapy-Induced Cellular Reprogramming and Novel Therapeutic Targets in Relapsed/refractory Acute Myeloid Leukemia

Emerging agents for treatment of the relapsed/refractory multiple myeloma: reports from the 56th American Society of Hematology annual meeting

The 56th American Society of Hematology Annual Meeting: Advances in Clinical Trials on Relapse/refractory Acute Myeloid Leukemia

Current status and research directions in acute myeloid leukemia

Allogeneic Stem Cell Transplantation in Refractory Acute Myeloid Leukaemia

Exploiting cellular pathways to develop new treatment strategies for AML

Cmar_a_199817 3187..3196